Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Medicenna Therapeutics Corp. has unveiled promising preclinical data showcasing the potential of their novel therapies, MDNA11 and Bizaxofusp, in treating aggressive cancers like glioblastoma. These therapies work together to boost immune response and weaken the tumor microenvironment, offering hope for cancers resistant to current treatments. The combination of MDNA11 and Bizaxofusp could revolutionize cancer treatment strategies, particularly for tumors known as ‘cold tumors.’
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money